DNTH

Short Interest Trends: The report highlights significant changes in short interest for various stocks, including CleanSpark and Mara Holdings, which saw increases in short interest percentages alongside fluctuating stock prices influenced by the cryptocurrency market.

Stock Performance Overview: Celsius Holdings experienced a notable decline in short interest due to improved performance and positive news, while other stocks like EVgo faced rising bearish activity despite recent gains.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Financial Performance: Dianthus Therapeutics reported Q4 revenue of $1.33 million, exceeding the consensus estimate of $859,700, and is on track to provide top-line data from its Phase 2 clinical trial in gMG by the second half of 2025.

Clinical Trials Update: The company has initiated its pivotal Phase 3 CAPTIVATE trial in CIDP, with an interim responder analysis expected in the second half of 2026, alongside anticipated results from its Phase 2 trial in MMN.

Analyst Rating: Alex Thompson from Stifel Nicolaus maintains a Buy rating on Dianthus Therapeutics (DNTH) with a price target of $52.00, while the current analyst consensus is a Strong Buy with an average price target of $49.40.

Market Overview: Dianthus Therapeutics has a market cap of $682.2M and a P/E ratio of -9.23, with Thompson's average return at -1.2% and a success rate of 39.13% on his stock recommendations.

Company Participation in Conferences: Dianthus Therapeutics will participate in two healthcare investor conferences in February, including a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6 and another at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12.

About Dianthus Therapeutics: The company is focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, led by an experienced team based in New York City and Waltham, Mass.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Short Interest Trends: The report highlights significant changes in short interest for various stocks, with Archer Aviation seeing a notable increase in investor interest and short positioning rising from 20% to 24%, while Dianthus Therapeutics experienced a spike in short interest from 34.9% to 42.3%.

Stock Performance Overview: Soleno Therapeutics and AMC Networks saw declines in short interest percentages, with Soleno dropping from 23.9% to 15.4% after positive FDA news, and AMC's short interest falling from 20.8% to 17.3% despite the stock being down about 50% year-to-date.

U.S. Stock Market Update: U.S. stock futures are up, with Dow futures increasing by 0.2%, while several companies, including Powell Industries and Target Corporation, experienced significant declines in pre-market trading due to disappointing quarterly results.

Stock Performance Highlights: Powell Industries shares fell 15.4% after missing sales estimates, while other notable declines included Target down 16.3%, Destiny Tech100 down 13.4%, and XP Inc down 4.1% following weak earnings reports.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Analyst Ratings Overview: Over the past three months, Dianthus Therapeutics has received mixed analyst ratings, with 2 bullish and 2 somewhat bullish opinions, while the average 12-month price target has increased to $46.00, reflecting positive sentiment among some analysts.

Company Performance Metrics: Dianthus Therapeutics demonstrates strong financial metrics, including a remarkable revenue growth rate of 92.26%, a net margin exceeding industry averages, and effective debt management with a debt-to-equity ratio of 0.0, indicating a solid market position despite challenges in the healthcare sector.

Analyst Rating: Rami Katkhuda from LifeSci Capital maintains a Buy rating on Dianthus Therapeutics (DNTH) with a price target of $45.00, citing the company's strong financial position and advancements in its drug pipeline, particularly the Phase III trial for DNTH103.

Company Overview: Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines for bone marrow transplants, founded in 2015 and headquartered in Cambridge, MA.

Dianthus Therapeutics Stock Performance: Dianthus Therapeutics, Inc. (DNTH) shares increased by 5.7% to $27.99, driven by optimism surrounding its lead candidate DNTH103 for autoimmune diseases, despite a projected quarterly loss of $0.59 per share.

Earnings Estimate Trends: The consensus EPS estimate for DNTH has been revised 4% higher recently, indicating potential price appreciation, while the stock holds a Zacks Rank #3 (Hold).

Options Trading Activity: Booking Holdings Inc (BKNG) has seen significant options trading with 2,491 contracts representing 120.5% of its average daily volume, particularly for the $3880 strike call option expiring October 11, 2024.

Dianthus Therapeutics Options Volume: Dianthus Therapeutics Inc (DNTH) also reported high options activity with 2,752 contracts traded, equating to 115% of its average daily volume, notably for the $30 strike call option expiring November 15, 2024.

Analyst Coverage and Price Target: Oppenheimer has initiated coverage of Dianthus Therapeutics with an Outperform recommendation, projecting an 86.62% upside to a one-year price target average of $51.34/share from its current price of $27.51/share.

Institutional Ownership Trends: There has been a notable increase in institutional ownership of Dianthus Therapeutics, with 144 funds reporting positions, a 20% rise in owners over the last quarter, and significant increases in share allocations by major investors like Bain Capital and Avidity Partners.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Ulta Beauty's Earnings Report: Ulta Beauty, Inc. shares fell 6.4% in pre-market trading after reporting second-quarter earnings of $5.30 per share, missing estimates, and cutting its FY24 guidance.

Other Stocks Performance: Several stocks experienced significant losses in pre-market trading, including Elastic N.V. down 27.1%, Autozi Internet Technology down 6.9%, and Nokia Oyj down 2.2%.

Put Selling and Market Dynamics: Selling a put option on Dianthus Therapeutics Inc does not provide the same upside potential as owning shares, as the seller only benefits from the premium unless the stock price falls significantly. The current market conditions indicate that the $25 strike price may offer a 26.1% annualized return if exercised.

Trading Volume Insights: Recent trading data shows an increase in put options volume among S&P 500 components, with a put:call ratio of 0.75, suggesting more put buyers than expected compared to historical averages.

Earnings Report: Dianthus Therapeutics reported a second-quarter 2024 earnings per share of -51 cents, surpassing the analyst estimate of -55 cents, and generated revenue of $1.86 million, significantly exceeding the expected $322,750 by 477.23%.

Automated Coverage: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly provide key financial figures and comparisons to analyst estimates without human intervention.